Academic Journal
CRISPRa-identified transcription factors reprogram glioblastoma into dendritic cell-like cells to elicit systemic antitumor immunity.
| Τίτλος: | CRISPRa-identified transcription factors reprogram glioblastoma into dendritic cell-like cells to elicit systemic antitumor immunity. |
|---|---|
| Συγγραφείς: | Liu X; State Key Laboratory of Cancer Biology, Biotechnology Center, School of Pharmacy, The Fourth Military Medical University, Xi'an 710000, China; Department of Neurosurgery, Xijing Hospital, Xi'an 710000, China., Zhu M; State Key Laboratory of Cancer Biology, Biotechnology Center, School of Pharmacy, The Fourth Military Medical University, Xi'an 710000, China., Zou C; State Key Laboratory of Cancer Biology, Biotechnology Center, School of Pharmacy, The Fourth Military Medical University, Xi'an 710000, China., Cao Z; State Key Laboratory of Cancer Biology, Biotechnology Center, School of Pharmacy, The Fourth Military Medical University, Xi'an 710000, China., Wang Y; Air Force Medical Center of PLA, Air Force Medical University, Beijing 100000, China., Yang G; Department of Neurosurgery, Xijing Hospital, Xi'an 710000, China., Liu X; State Key Laboratory of Cancer Biology, Biotechnology Center, School of Pharmacy, The Fourth Military Medical University, Xi'an 710000, China., Wu Y; State Key Laboratory of Cancer Biology, Biotechnology Center, School of Pharmacy, The Fourth Military Medical University, Xi'an 710000, China., Yu D; Department of Neurosurgery, General Hospital of Central Theater Command, Wuhan, China., Zheng D; State Key Laboratory of Cancer Biology, Biotechnology Center, School of Pharmacy, The Fourth Military Medical University, Xi'an 710000, China., Zhang K; State Key Laboratory of Cancer Biology, Biotechnology Center, School of Pharmacy, The Fourth Military Medical University, Xi'an 710000, China., Li J; Department of Neurosurgery, Xijing Hospital, Xi'an 710000, China., Zhang W; State Key Laboratory of Cancer Biology, Biotechnology Center, School of Pharmacy, The Fourth Military Medical University, Xi'an 710000, China., Wang S; State Key Laboratory of Cancer Biology, Biotechnology Center, School of Pharmacy, The Fourth Military Medical University, Xi'an 710000, China., Qin H; Department of Neurosurgery, Xijing Hospital, Xi'an 710000, China., Hao Q; State Key Laboratory of Cancer Biology, Biotechnology Center, School of Pharmacy, The Fourth Military Medical University, Xi'an 710000, China., Zhang Y; State Key Laboratory of Cancer Biology, Biotechnology Center, School of Pharmacy, The Fourth Military Medical University, Xi'an 710000, China., Yin A; Department of Plastic and Reconstructive Surgery, Xijing Hospital, Fourth Military Medical University, Xi'an, China., He Y; Department of Neurosurgery, Xijing Hospital, Xi'an 710000, China., He L; State Key Laboratory of Cancer Biology, Biotechnology Center, School of Pharmacy, The Fourth Military Medical University, Xi'an 710000, China., Luo X; School of Basic Medicine, Fourth Military Medical University, Xi'an, China. Electronic address: 631912271@qq.com., Lin W; Department of Neurosurgery, Xijing Hospital, Xi'an 710000, China; Department of Aviation Medicine, Xijing Hospital, Xi'an, China. Electronic address: linwei@fmmu.edu.cn., Li M; State Key Laboratory of Cancer Biology, Biotechnology Center, School of Pharmacy, The Fourth Military Medical University, Xi'an 710000, China. Electronic address: limeng@fmmu.edu.cn., Gu J; State Key Laboratory of Cancer Biology, Biotechnology Center, School of Pharmacy, The Fourth Military Medical University, Xi'an 710000, China. Electronic address: gujintao@fmmu.edu.cn. |
| Πηγή: | Cell reports. Medicine [Cell Rep Med] 2026 Sep 15; Vol. 7 (9), pp. 103018. Date of Electronic Publication: 2026 Sep 01. |
| Τύπος έκδοσης: | Journal Article |
| Γλώσσα: | English |
| Στοιχεία περιοδικού: | Publisher: Cell Press Country of Publication: United States NLM ID: 101766894 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 2666-3791 (Electronic) Linking ISSN: 26663791 NLM ISO Abbreviation: Cell Rep Med Subsets: MEDLINE |
| Imprint Name(s): | Original Publication: [Cambridge, MA] : Cell Press, [2020]- |
| Ιατρικοί όροι (MeSH): | Glioblastoma*/immunology , Glioblastoma*/genetics , Glioblastoma*/pathology , Glioblastoma*/therapy , Dendritic Cells*/immunology , Dendritic Cells*/metabolism , Transcription Factors*/metabolism , Transcription Factors*/genetics , Cellular Reprogramming*/genetics , Brain Neoplasms*/immunology , Brain Neoplasms*/pathology , Brain Neoplasms*/genetics, Tumor Microenvironment/immunology ; Immunotherapy/methods ; Animals ; Humans ; Mice ; Cell Line, Tumor ; Gene Expression Regulation, Neoplastic |
| Περίληψη: | Although immunotherapy has transformed the treatment landscape for many types of cancer, its therapeutic efficacy in glioblastoma (GBM) is limited by insufficient antigen presentation and the immunogenic cell exclusion in the tumor microenvironment. Here, we develop a candidate-based CRISPR activation (CRISPRa) functional screen to identify regulators of conventional dendritic cell (cDC)-fate specification. We determine that the transcription factors Zfp366/Znf366, Pu.1, Irf8, and Batf3 (ZPIB) are sufficient to convert GBM cells into cDC-like cells. ZPIB-mediated reprogramming results in global transcriptional and epigenetic remodeling in glioma cells. Single-cell RNA sequencing (scRNA-seq) profiling also reveals efficient and dynamic reprogramming of GBM cells to cDCs in vivo. Moreover, reprogrammed tumor cells remodel the microenvironment and elicit systemic tumor-eradicating and durable antitumor immunity in multiple mouse GBM models. Antitumor immunity elicited by ZPIB-DCs is synergistic with immune checkpoint inhibitors. Finally, we evaluate the clinical applicability of this approach by generating ZPIB-DCs from GBM patients within a humanized model. Our study represents a cellular reprogramming therapeutic strategy with broad implications for clinical immunotherapy. (Copyright © 2026 The Author(s). Published by Elsevier Inc. All rights reserved.) |
| Competing Interests: | Declaration of interests The authors declare no competing interests. |
| References: | Brain Res. 2017 Feb 1;1656:2-13. (PMID: 26475975) Acc Chem Res. 2022 Jan 4;55(1):2-12. (PMID: 34850635) Cell. 2025 Aug 21;188(17):4622-4639.e19. (PMID: 40499543) Nat Rev Immunol. 2024 Mar;24(3):213-227. (PMID: 37783860) Sci Immunol. 2021 Apr 2;6(58):. (PMID: 33811060) Cell. 2007 Nov 30;131(5):861-72. (PMID: 18035408) Nat Rev Mol Cell Biol. 2016 Mar;17(3):183-93. (PMID: 26883003) Neuro Oncol. 2018 Feb 19;20(3):343-354. (PMID: 29016888) Immunity. 2020 Aug 18;53(2):353-370.e8. (PMID: 32735845) Blood. 2007 Dec 15;110(13):4341-50. (PMID: 17855630) Cell Stem Cell. 2021 Dec 2;28(12):2104-2121.e10. (PMID: 34592167) Nat Cell Biol. 2023 Aug;25(8):1121-1134. (PMID: 37460697) Annu Rev Med. 2018 Jan 29;69:301-318. (PMID: 29414259) Nature. 2025 Jun;642(8067):508-518. (PMID: 40240608) Adv Drug Deliv Rev. 2023 Sep;200:114990. (PMID: 37423563) ACS Biomater Sci Eng. 2019 Sep 9;5(9):4263-4271. (PMID: 33417782) Semin Immunol. 2013 Oct 31;25(3):219-27. (PMID: 23548749) Adv Drug Deliv Rev. 2024 Mar;206:115190. (PMID: 38307296) Cancers (Basel). 2024 Jun 13;16(12):. (PMID: 38927916) Lancet. 2023 Oct 28;402(10412):1564-1579. (PMID: 37738997) Nat Rev Drug Discov. 2024 Sep;23(9):709-722. (PMID: 38965378) Cell Res. 2019 Feb;29(2):124-135. (PMID: 30560924) Nature. 2025 Aug;644(8078):1097-1106. (PMID: 40562937) Nat Rev Mol Cell Biol. 2021 Jun;22(6):410-424. (PMID: 33619373) Cell Stem Cell. 2015 Aug 6;17(2):195-203. (PMID: 26253201) N Engl J Med. 2024 Apr 11;390(14):1290-1298. (PMID: 38477966) Development. 2024 Oct 1;151(19):. (PMID: 39348466) Sci Immunol. 2018 Dec 7;3(30):. (PMID: 30530727) Cell. 2019 Feb 7;176(4):928-943.e22. (PMID: 30712874) Science. 2024 Oct 18;386(6719):eadn9083. (PMID: 39236156) J Biol Chem. 2024 Dec;300(12):107994. (PMID: 39547513) Nat Rev Cancer. 2016 Aug 23;16(9):566-81. (PMID: 27550819) Science. 2023 Jun 23;380(6651):1258-1265. (PMID: 37347855) Immunity. 2025 May 13;58(5):1140-1160. (PMID: 40324379) Neuron. 2020 Oct 14;108(1):128-144.e9. (PMID: 32810432) Life Med. 2022 Aug 30;1(2):49-51. (PMID: 39871925) Cell. 2016 Dec 15;167(7):1719-1733.e12. (PMID: 27984723) Trends Cell Biol. 2024 Mar;34(3):255-267. (PMID: 37648593) Cancer Immunol Res. 2024 Oct 1;12(10):1340-1360. (PMID: 39051633) Stem Cell Reports. 2019 Dec 10;13(6):1126-1141. (PMID: 31813827) Lancet Oncol. 2022 Oct;23(10):e450-e458. (PMID: 36174631) Cancer Cell. 2019 Jan 14;35(1):17-32.e6. (PMID: 30645973) Cell. 2022 Jul 21;185(15):2770-2788. (PMID: 35835100) N Engl J Med. 2021 Aug 05;385(6):493-502. (PMID: 34215024) Nature. 2022 Nov;611(7937):744-753. (PMID: 36289336) Trends Mol Med. 2025 Sep;31(9):814-826. (PMID: 39966070) Immunity. 2017 Jan 17;46(1):65-77. (PMID: 27986456) Circ Res. 2015 Apr 10;116(8):1378-91. (PMID: 25858064) |
| Contributed Indexing: | Keywords: CRISPR screen; cancer immunotherapy; glioblastoma; lineage reprogramming; tumor microenvironment |
| Substance Nomenclature: | 0 (Transcription Factors) |
| Entry Date(s): | Date Created: 20260901 Date Completed: 20260915 Latest Revision: 20260922 |
| Update Code: | 20260922 |
| PubMed Central ID: | PMC13589486 |
| DOI: | 10.1016/j.xcrm.2026.103018 |
| PMID: | 42679804 |
| Βάση Δεδομένων: | MEDLINE |
| ISSN: | 2666-3791 |
|---|---|
| DOI: | 10.1016/j.xcrm.2026.103018 |